Trifecta Capital Advisors LLC Raises Stock Position in Boston Scientific Corporation $BSX

Key Points

• Trifecta Capital Advisors LLC increased its stake in Boston Scientific Corporation by 6.9%, acquiring a total of 46,411 shares valued at approximately $4.99 million.
• Several institutional investors, including Activest Wealth Management, significantly raised their positions, reflecting escalated interest in Boston Scientific, which has 89.07% of its stock held by institutional investors.
• Boston Scientific's stock received a range of analyst ratings, with the consensus indicating a "Buy" and an average target price of $120.71, after various price adjustments and ratings changes by firms like Leerink Partners and Needham & Company.

Trifecta Capital Advisors LLC grew its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 6.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,411 shares of the medical equipment provider's stock after purchasing an additional 3,010 shares during the period. Trifecta Capital Advisors LLC's holdings in Boston Scientific were worth $4,985,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. 1248 Management LLC purchased a new position in shares of Boston Scientific during the first quarter valued at about $26,000. Y.D. More Investments Ltd purchased a new position in shares of Boston Scientific during the first quarter valued at about $27,000. Sound Income Strategies LLC grew its position in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 120 shares in the last quarter. Oliver Lagore Vanvalin Investment Group purchased a new position in shares of Boston Scientific during the second quarter valued at about $37,000. Finally, Activest Wealth Management grew its position in shares of Boston Scientific by 6,216.7% during the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider's stock valued at $38,000 after purchasing an additional 373 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on BSX shares. Leerink Partners raised their price objective on Boston Scientific from $127.00 to $128.00 and gave the company an "outperform" rating in a research report on Wednesday, October 1st. Needham & Company LLC reaffirmed a "buy" rating and issued a $121.00 price target on shares of Boston Scientific in a report on Wednesday, October 1st. Evercore ISI lowered their price target on shares of Boston Scientific from $115.00 to $110.00 and set an "outperform" rating for the company in a report on Tuesday. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Finally, Wall Street Zen downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $120.71.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director directly owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Up 0.9%

Shares of NYSE BSX opened at $96.73 on Thursday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market cap of $143.33 billion, a P/E ratio of 57.58, a PEG ratio of 2.31 and a beta of 0.61. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The firm has a 50-day simple moving average of $102.34 and a two-hundred day simple moving average of $101.96.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm's quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.